Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
暂无分享,去创建一个
[1] L Janish,et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Relling,et al. Variability in Teniposide Plasma Protein Binding Is Correlated With Serum Albumin Concentrations , 1992, Pharmacotherapy.
[3] I Gordon,et al. Normalization of glomerular filtration rate in children: body surface area, body weight or extracellular fluid volume? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] A. Boddy,et al. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. , 1993, Cancer research.
[5] E. Jaffe,et al. Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Cole,et al. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. , 1993, Cancer research.
[7] A. Paine. Review : Heterogeneity of cytochrome P450 and its toxicological significance , 1995, Human & experimental toxicology.
[8] W. Evans,et al. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. , 2010, Arthritis and rheumatism.
[9] M. Schnegg,et al. Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. , 1986, Journal of hepatology.
[10] R. Diasio,et al. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Bonadonna,et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Peterson,et al. Large Interindividual Variations in the Pharmacokinetics of Oral 6‐Mercaptopurine in Maintenance Therapy of Children with Acute Leukaemia and Non‐Hodgkin Lymphoma , 1986, Acta paediatrica Scandinavica.
[13] K. Shimokata,et al. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M Slavik,et al. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. , 1975, Cancer research.
[15] J G Fryer,et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Egorin,et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. , 1985, Cancer research.
[17] M. Relling,et al. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. , 1993, The Journal of clinical investigation.
[18] M. Egorin,et al. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. , 1986, Cancer research.
[19] R. Schilsky,et al. Pharmacodynamics in cancer therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] W. Plunkett,et al. Cellular pharmacodynamics of anticancer drugs. , 1993, Seminars in oncology.
[21] W. Bowman,et al. METHOTREXATE SYSTEMIC CLEARANCE INFLUENCES PROBABILITY OF RELAPSE IN CHILDREN WITH STANDARD-RISK ACUTE LYMPHOCYTIC LEUKAEMIA , 1984, The Lancet.
[22] D. Dodwell,et al. Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] R. Lipton,et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Relling,et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. , 1991, Seminars in hematology.
[25] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Tarone,et al. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. B. Campbell,et al. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. , 1983, Cancer treatment reports.
[28] M. Adams,et al. Bioequivalence of Two Methotrexate Formulations in Psoriatic and Cancer Patients , 1993, The Annals of pharmacotherapy.
[29] G. Rosner,et al. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. , 1993, Journal of the National Cancer Institute.
[30] R. Schilsky. Renal and metabolic toxicities of cancer chemotherapy. , 1982, Seminars in oncology.
[31] S. Piscitelli,et al. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer , 1994, Cancer.
[32] D. Greenblatt,et al. Drug Disposition in Obese Humans , 1986, Clinical pharmacokinetics.
[33] J. Crawford,et al. Simplification of drug dosage calculation by application of the surface area principle. , 1950, Pediatrics.
[34] R. Chlebowski,et al. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. , 1980, Cancer research.
[35] D. Kerr,et al. Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. , 1988, British Journal of Cancer.
[36] R. Schilsky,et al. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. , 1987, Cancer research.
[37] M. Namer,et al. Dose Versus pharmacokinetics for predicting tolerance to 5‐day continuous infusion of 5‐FU , 1988, International journal of cancer.
[38] J J Shuster,et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] W. Evans,et al. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. , 1993, Seminars in oncology.
[40] P. Langenberg,et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] C. Coltman,et al. Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. , 1977, Cancer treatment reports.
[42] C. Stein,et al. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. , 1993, Cancer research.
[43] C. Coltman,et al. Phase II evaluation of bleomycin. A Southwest Oncology Group study , 1976, Cancer.
[44] E J Freireich,et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.
[45] J. Borsi,et al. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia , 1987, Cancer.
[46] S. Ellenberg,et al. Correlates of severe or life-threatening toxic effects from trimetrexate. , 1988, Journal of the National Cancer Institute.
[47] E. Gehan,et al. Dose‐response and dose‐survival advantage for high versus low‐dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study , 1984, Cancer.
[48] M. Egorin,et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. , 1984, Cancer research.
[49] E. Frei,et al. Chemotherapy of malignant lymphoma with adriamycin. , 1973, Cancer research.
[50] R. Gelman,et al. Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents. , 1987, Cancer treatment reports.
[51] J. Lilleyman,et al. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R. Dorr,et al. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. , 1995, Cancer treatment reviews.
[53] M. Stevens,et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] A. Legendre,et al. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. , 1994, American journal of veterinary research.
[55] R. Schilsky,et al. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] T. Einarson,et al. The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents , 1992, The Annals of pharmacotherapy.
[57] R. Schilsky,et al. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). , 1994, Cancer research.
[58] S. Guandalini,et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. , 1991, Therapeutic drug monitoring.
[59] M. Caulfield,et al. Protein binding of indomethacin, methotrexate and morphine in patients with cancer. , 1992, International journal of clinical pharmacology research.
[60] M. Egorin,et al. Cancer pharmacology in the elderly. , 1993, Seminars in Oncology.
[61] M. Ratain,et al. Individualizing dosing of cancer chemotherapy. , 1993, Seminars in oncology.
[62] L. Grochow,et al. Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity. , 1988, Journal of the National Cancer Institute.
[63] Y. Rustum,et al. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. , 1982, Cancer research.
[64] D. Rushing,et al. Doxorubicin clearance in the obese. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] M. Relling,et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] J. Blom,et al. Amputation and adriamycin in primary osteosarcoma. , 1974, The New England journal of medicine.
[67] H. Wieand,et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] S. Rosenberg,et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. , 1977, The New England journal of medicine.
[69] S. Baker,et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] N. Dobbs,et al. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. , 1992, British Journal of Cancer.
[71] W. Evans,et al. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] W. Evans,et al. Altered protein binding of etoposide in patients with cancer , 1989, Clinical pharmacology and therapeutics.
[73] W. Woods,et al. Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. , 1981, The Journal of pediatrics.
[74] J. Zalcberg,et al. Lean body mass, body surface area and epirubicin kinetics. , 1994, Anti-cancer drugs.
[75] E. Frei,et al. Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.
[76] E. Gillette,et al. Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog. , 1988, Cancer research.
[77] R. Ozols,et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. , 1994, Cancer research.
[78] W. J. Childs,et al. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[79] Antonius A. Miller,et al. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] D. DuBois,et al. A formula to estimate the approximate surface area if height and weight be known , 1989 .
[81] R. Herrmann,et al. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. , 1991, Oncology.
[82] T. Chou,et al. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. , 1987, Cancer research.
[83] D. Pinkel. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. , 1958, Cancer research.
[84] G. Blackledge,et al. Prediction of ifosfamide/mesna associated encephalopathy. , 1986, European journal of cancer & clinical oncology.
[85] W. Evans,et al. Therapeutic drug monitoring in cancer management. , 1993, Clinical chemistry.
[86] B. Chabner,et al. Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion. , 1978, Drug metabolism reviews.
[87] H. Preisler,et al. Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. , 1987, Seminars in oncology.
[88] T. L. Evans,et al. Oral melphalan kinetics , 1979, Clinical pharmacology and therapeutics.
[89] P. Watkins,et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. , 1989, The Journal of clinical investigation.
[90] R. Gelman,et al. Dose-response in the treatment of breast cancer: a critical review. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] X. J. Zhou,et al. Pharmacokinetics and metabolism of vinca alkaloids. , 1993, Cancer surveys.
[92] L. Einhorn,et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.
[93] W. Dawson. RELATIONS BETWEEN AGE AND WEIGHT AND DOSAGE OF DRUGS , 1940 .
[94] J. Rodman,et al. The pharmacokinetics of high‐dose carboplatin in pediatric patients with cancer , 1992, Clinical pharmacology and therapeutics.
[95] J. Carpenter,et al. Favorable factors in the adjuvant therapy of breast cancer , 1982, Cancer.
[96] J. Earle,et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] S. Piscitelli,et al. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer , 1993, Clinical pharmacology and therapeutics.
[98] M. Relling,et al. Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.
[99] M. Egorin,et al. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. , 1987, Cancer research.
[100] A. Sulkes,et al. Reappraisal of some dosage adjustment guidelines. , 1987, Cancer treatment reports.
[101] G. Vassal,et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? , 1992, Blood.
[102] R. Schilsky,et al. Phase I study of amonafide dosing based on acetylator phenotype. , 1993, Cancer research.
[103] Joseph R. Bertino,et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.
[104] J. Lilleyman,et al. 6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukaemia. , 1982, British Journal of Cancer.
[105] Homer W. Smith. The Kidney: Structure and Function in Health and Disease , 1952 .
[106] O. Björk,et al. The Course of Biological Parameters and 6‐Mercaptopurine Pharmacokinetics during Maintenance Treatment of Children with Acute Lymphoblastic Leukaemia , 1990, Acta paediatrica Scandinavica.
[107] D. Dearnaley,et al. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] C. Erlichman. Potential applications of therapeutic drug monitoring in treatment of neoplastic disease by antineoplastic agents. , 1986, Clinical biochemistry.
[109] R. Schilsky,et al. High-dose methotrexate: a critical reappraisal. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] W. Evans,et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] S. Loft,et al. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. , 1988, Journal of hepatology.
[112] N. Bachur,et al. Acute doxorubicin toxicity relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia , 1984, Cancer.
[113] G. Bonadonna,et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.
[114] H. Kunitoh,et al. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] M. Moore,et al. Therapeutic Drug Monitoring in Oncology , 1987, Clinical pharmacokinetics.
[116] E. Mihich,et al. The clinical toxicity of anticancer drugs and its prediction. , 1977, Seminars in oncology.
[117] S L George,et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.
[118] C. Patte,et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] R. Simon,et al. Tolerance to antineoplastic agents in children and adults. , 1985, Cancer treatment reports.
[120] E K Rowinsky,et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] R. Fisher,et al. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. , 1987, Seminars in hematology.
[122] L. Grochow,et al. Is dose normalization to weight or body surface area useful in adults? , 1990, Journal of the National Cancer Institute.
[123] W. Evans,et al. Disposition of antineoplastic agents in the very young child. , 1992, The British journal of cancer. Supplement.
[124] S. Steinberg,et al. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. , 1990, Cancer research.
[125] F. Cavalli,et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. , 1986, Cancer research.
[126] A. Santoro,et al. Alternating drug combinations in the treatment of advanced Hodgkin's disease. , 1982, The New England journal of medicine.
[127] A. Caraceni,et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] C. Stewart,et al. Disposition of high‐dose methotrexate in an obese cancer patient , 1991, Cancer.
[129] D. Greenblatt,et al. Pharmacokinetic aspects of drug therapy in the elderly. , 1986, Therapeutic drug monitoring.
[130] S. Steinberg,et al. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. , 1995, Journal of the National Cancer Institute.
[131] P. Johnston,et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.
[132] K. Eguchi,et al. A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38 , 1995, Japanese journal of cancer research : Gann.
[133] E. Gehan,et al. Estimation of human body surface area from height and weight. , 1970, Cancer chemotherapy reports.
[134] X. J. Zhou,et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. , 1993, Cancer research.
[135] L. Grochow,et al. Should anticancer drug doses be adjusted in the obese patient? , 1995, Journal of the National Cancer Institute.
[136] J. Zalcberg,et al. Serum methotrexate in childhood ALL. , 1992, British Journal of Cancer.
[137] D. Jodrell,et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] R. Rubens,et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. , 1987, British Journal of Cancer.
[139] M. Ratain,et al. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. , 1993, Cancer surveys.
[140] M. Relling,et al. Hepatic drug clearance in children: studies with indocyanine green as a model substrate. , 1989, Journal of pharmaceutical sciences.
[141] M. Relling,et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[143] M. Piccart,et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. , 1990, Journal of the National Cancer Institute.
[144] R. Epstein,et al. Drug-induced DNA damage and tumor chemosensitivity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.